Shares of Omeros Corp (OMER) are trading 9% higher at a price of $3.435 at the time of this writing. The Health Care sector is having a generally optimistic day, this hasn't really affected the stock's share price, as it flying high above other names in the space. The market is undergoing a significant macro move (2.13%) which could be a factor in the stock's movement.
-Omeros Corporation has announced a royalty monetization transaction with DRI Healthcare Trust.
Omeros Corp has been trading between a 52-week high of $8.6 and a 52-week low of $1.86. The stock has a market cap of $215 Million.
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.